COG-AALL1732
Phase III
OPEN TO ACCRUAL
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
COG-AALL1821
Phase II
OPEN TO ACCRUAL
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
COG-AAML1831
Phase III
OPEN TO ACCRUAL
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
IIT-BURKE-VENETOCLAX-EPIGENETI
Phase I
OPEN TO ACCRUAL
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients with Relapsed and Refractory Acute Myeloid Leukemia
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation